Gersizangitide

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameGersizangitide
Drug Alias NameAXT-107
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsTEK receptor tyrosine kinase agonists
TargetsVascular endothelial growth factor receptor 2TEK receptor tyrosine kinase
Therapy Area/IndicationsDiabetic macular oedemaMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAsclepiX Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesAsclepiX Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMacular Degeneration
Inactive IndicationsDiabetic macular oedema

Other Information

ATC CodeN/A
Related LinksN/A